MedTrace Logo

Comparison of Two Botulinum Type A Products in the Treatment of Blepharospasm

NCT00761592 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 65

Last updated 2013-11-19

Study results available
· View outcomes & findings →

Summary

This pilot study estimates the treatment effects of two different types of botulinum toxin type A in the treatment of Blepharospasm. Blepharospasm is characterised by excessive contraction of the muscles around the eye and can lead to repetitive blinking or sustained closure of the eyelids.

Conditions

  • Blepharospasm

Interventions

BIOLOGICAL

Botulinum Toxin Type A 900kDa

6 to 16 injections, with maximum of 21, at a dose of ≥20U/eye (≥40U total dose)

BIOLOGICAL

Botulinum Toxin Type A 150kDa

6 to 16 injections, with a maximum of 21, at a dose of ≥20U/eye (≥40U total dose)

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Medical Director · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2008-01-31
Completion
2008-01-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00761592 on ClinicalTrials.gov